Piper Sandler analyst Jessica Tassan raised the firm’s price target on CVS Health (CVS) to $101 from $99 and keeps an Overweight rating on the shares. The firm says CVS established guidance for a three year mid-teens adjusted EPS CAGR led by the ongoing margin recovery at HCB. This outlook very conservatively gets us to $9.41 of adjusted EPS in 2028 with buybacks offering upside and rendering $10.00 readily achievable within the forecast period. Guidance assumes buybacks are suspended in 2026 as CVS prioritizes deleveraging; and resume in 2027 and 2028 only to offset dilution.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health price target raised to $93 from $87 at Barclays
- CVS Health price target raised to $97 from $96 at UBS
- CVS Health: Strong Financial Outlook and Strategic Initiatives Drive Buy Rating
- CVS Health’s Promising Growth Trajectory and Strategic Focus Drive Buy Rating
- CVS Health: Strategic Initiatives and Financial Outlook Drive Buy Rating